Clinical trialNCT02501811CompletedPhase 2Interventional

Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure

SponsorThe University of Texas Health Science Center, HoustonEnrollment125Ischemic Cardiomyopathy

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a phase II, randomized, placebo-controlled clinical trial designed to assess feasibility, safety, and effect of autologous bone marrow-derived mesenchymal stem cells (MSCs) and c-kit+ cells both alone and in combination (Combo), compared to placebo (cell-free Plasmalyte-A medium) as well as each other, administered by transendocardial injection in subjects with ischemic cardiomyopathy.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Robert Simari, MD
CCTRN Steering Committee Chair
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Stanford University School of Medicine (falk Cardiovascular Research Center)
Stanford, California, United States
University of Florida-Department of Medicine
Gainesville, Florida, United States
University of Miami-Interdisciplinary Stem Cell Institute
Miami, Florida, United States
Indiana Center for Vascular Biology and Medicine
Indianapolis, Indiana, United States
University of Louisville
Louisville, Kentucky, United States
Minneapolis Heart Institute Foundation
Minneapolis, Minnesota, United States
Texas Heart Institute
Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Mesenchymal Stem CellsPlaceboC-kit+ cells

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Oct 2015
Primary completion: 25 Jun 2020
Completion: 22 Jul 2020
Last update posted: 26 Apr 2021
Registered enrollment: 125
Registry id: NCT02501811

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.